Here are the S-3 shelf registrations from Phathom Pharmaceuticals, Inc. (PHAT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow PHAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PHAT filings page.
Phathom Pharmaceuticals has registered 5,827,415 shares of common stock for potential resale by a large stockholder, with all sale proceeds going to that holder rather than the company.
Separately, as a well-known seasoned issuer, Phathom has filed an automatic shelf registration on Form S-3 that allows it to offer common stock, preferred stock, debt securities, warrants and units from time to time, with specific terms and uses of proceeds to be detailed in future prospectus supplements.
The company focuses on gastrointestinal treatments built around vonoprazan, the active ingredient in its VOQUEZNA-branded products for conditions such as erosive GERD and H. pylori infection.